Allogene Therapeutics (ALLO) EBITDA (2018 - 2026)

Allogene Therapeutics has reported EBITDA for 9 years, with the latest figure at -$46.1 million in Q1 2026.

• Quarterly EBITDA rose 29.3% year-over-year to -$46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$190.2 million (up 29.26% YoY) and the FY2025 annual result came in at -$209.3 million, up 23.38% from the prior year.
• EBITDA declined to -$46.1 million in Q1 2026 per ALLO's latest filing, from -$42.4 million in the prior quarter.
• Over five years, EBITDA peaked at -$42.4 million in Q4 2025 and troughed at -$99.1 million in Q1 2023.
• A 5-year average of -$70.1 million and a median of -$71.4 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2025: EBITDA slumped 5747.04% in 2022, then soared 37.44% in 2025.
• Over 5 years, EBITDA stood at -$96.4 million in 2022, then climbed by 11.71% to -$85.1 million in 2023, then increased by 28.93% to -$60.5 million in 2024, then increased by 29.9% to -$42.4 million in 2025, then slipped by 8.7% to -$46.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$46.1 million, -$42.4 million, and -$44.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.